USA flag logo/image

An Official Website of the United States Government

Control of Arthritic Pain by Inhibition of TRPA1 Activity

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43HL120529
Solicitation Year:
2013
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA12-088
Small Business Information
KORONIS BIOMEDICAL TECHNOLOGIES CORPORAT
6901 E Fish Lake Road Maple Grove, MN -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Control of Arthritic Pain by Inhibition of TRPA1 Activity
Agency: HHS
Contract: 1R43HL120529-01
Award Amount: $213,597.00
 

Abstract:

DESCRIPTION (provided by applicant): Koronis Biomedical Technologies (KBT) proposes a novel tool to test the integrity of implantable cardioverter- defibrillator (ICD) leads in-situ. Siilar to pacemakers, ICDs are surgically implanted just under the skin outside of the patient's rib cage. An ICD lead, which is a unified bundle of several insulated conductor cables, passes under the clavicle and through a vein to the chambers of the heart. While ICDs have been very effective at preventing sudden cardiac death, there have been repeated problems with ICD lead failures that have resulted in inappropriate shocks, failure to shock, ineffective cardioversion, and death. ICD leads fail over time and the longevity is difficult to predict and can be affected b the ageand activity level of a patient. Early diagnosis of ICD lead anomalies is important to reduce morbidity and/or mortality from loss of pacing, inappropriate ICD shocks, and/or ineffective treatment of ventricular tachycardia or ventricular fibrillation. However, existing technology for diagnosis of lead anomalies has significant limitations and shortcomings. New tools are needed. A major goal of the proposed tester is the identification of lead anomalies at the subclinical stage, before they present as a clinical problem. The proposed testing tool will be initially applied intraoperatively during ICD replacement procedures and in the future integrated directly into ICDs. Phase 1 will model, simulate, develop, and evaluate a prototype tester. Phase 2 will develop a production prototype tester and undertake efficacy evaluations in humans. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: An implantable cardioverter-defibrillator (ICD) is a small battery-powered electrical impulse generator that is implanted in patients who are at risk of sudden cardiac death due to ventricular fibrillation and ventricular tachycardia. The device is programmed to detect cardiac arrhythmia and correct it by delivering a jolt of electricity. Implantable cardioverter defibrillators have demonstrated clear life-saving benefits.

Principal Investigator:

Dan Kollmann
763-515-5321
dkollmann@koronisbiotech.com

Business Contact:

Patrick Lichter
763-515-5321
plichter@koronisbiotech.com
Small Business Information at Submission:

KORONIS BIOMEDICAL TECHNOLOGIES CORPORAT
6901 E Fish Lake Road Maple Grove, MN -

EIN/Tax ID: 141194323
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No